Literature DB >> 22741811

Treatment possibilities for individuals at clinical high risk of psychosis.

Kali Brummitt1, Jean Addington.   

Abstract

AIM: The purpose of this study was to undertake a first step in trying to understand the types of treatments young people at clinical high risk of psychosis are interested in pursuing.
METHODS: The sample consisted of 30 young people who were current participants in the ongoing North American Prodrome Longitudinal Study (NAPLS 2) and who met criteria for being at clinical high risk for psychosis. Participants were administered a questionnaire that asked them to identify the types of mental health problems they were currently getting help with or would like to get help with and the types of treatments they thought would be helpful and may be interested in receiving.
RESULTS: Results showed that when individuals first began participation in NAPLS, almost half had no expectations for treatment. They wanted help but they did not really know what kind of help to be asking for. Participants had a wide range of concerns for which they wanted help. Although a majority endorsed attenuated positive symptoms as a concern, many other issues such a family and social problems were often identified. For those who were already receiving help, the general opinion was that it was beneficial.
CONCLUSIONS: The findings suggest that this population sees many different interventions as being potentially helpful. Furthermore, they are open to participating in a variety of treatments, including psychotherapeutic and psychiatric interventions as well as more general treatments addressing a range of possible deficits or difficulties.
© 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22741811      PMCID: PMC3463741          DOI: 10.1111/j.1751-7893.2012.00370.x

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  15 in total

1.  Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk.

Authors:  Anthony P Morrison; Paul French; Sophie Parker; Morwenna Roberts; Helen Stevens; Richard P Bentall; Shôn W Lewis
Journal:  Schizophr Bull       Date:  2006-09-14       Impact factor: 9.306

Review 2.  Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions.

Authors:  Patrick D McGorry; Ian B Hickie; Alison R Yung; Christos Pantelis; Henry J Jackson
Journal:  Aust N Z J Psychiatry       Date:  2006-08       Impact factor: 5.744

3.  At clinical high risk for psychosis: outcome for nonconverters.

Authors:  Jean Addington; Barbara A Cornblatt; Kristin S Cadenhead; Tyrone D Cannon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Robert Heinssen
Journal:  Am J Psychiatry       Date:  2011-04-15       Impact factor: 18.112

4.  Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.

Authors:  Thomas H McGlashan; Robert B Zipursky; Diana Perkins; Jean Addington; Tandy Miller; Scott W Woods; Keith A Hawkins; Ralph E Hoffman; Adrian Preda; Irvin Epstein; Donald Addington; Stacy Lindborg; Quynh Trzaskoma; Mauricio Tohen; Alan Breier
Journal:  Am J Psychiatry       Date:  2006-05       Impact factor: 18.112

5.  Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity.

Authors:  Tandy J Miller; Thomas H McGlashan; Joanna Lifshey Rosen; Lubna Somjee; Philip J Markovich; Kelly Stein; Scott W Woods
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

Review 6.  Monitoring and care of young people at incipient risk of psychosis.

Authors:  A R Yung; P D McGorry; C A McFarlane; H J Jackson; G C Patton; A Rakkar
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

7.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

8.  Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial.

Authors:  Anthony P Morrison; Paul French; Lara Walford; Shôn W Lewis; Aoiffe Kilcommons; Joanne Green; Sophie Parker; Richard P Bentall
Journal:  Br J Psychiatry       Date:  2004-10       Impact factor: 9.319

9.  Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America.

Authors:  Tyrone D Cannon; Kristin Cadenhead; Barbara Cornblatt; Scott W Woods; Jean Addington; Elaine Walker; Larry J Seidman; Diana Perkins; Ming Tsuang; Thomas McGlashan; Robert Heinssen
Journal:  Arch Gen Psychiatry       Date:  2008-01

10.  Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group.

Authors:  Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Colleen A McFarlane; Mats Hallgren; Patrick D McGorry
Journal:  Schizophr Res       Date:  2003-03-01       Impact factor: 4.939

View more
  2 in total

Review 1.  Mental Health Services Research Targeting the Clinical High-Risk State for Psychosis: Lessons, Future Directions and Integration with Patient Perspectives.

Authors:  Sarah V McIlwaine; Jai Shah
Journal:  Curr Psychiatry Rep       Date:  2021-02-03       Impact factor: 5.285

2.  Effects of the Health-Awareness-Strengthening Lifestyle Program in a Randomized Trial of Young Adults with an At-Risk Mental State.

Authors:  Ching-Lun Tsai; Ya-Wen Lin; Hsing-Chi Hsu; Mei-Ling Lou; Hsien-Yuan Lane; Cheng-Hao Tu; Wei-Fen Ma
Journal:  Int J Environ Res Public Health       Date:  2021-02-18       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.